Banerjee Soma, Williamson Deborah A, Habib Nagy, Chataway Jeremy
Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK.
Vasc Health Risk Manag. 2012;8:569-80. doi: 10.2147/VHRM.S25745. Epub 2012 Oct 10.
Stroke is a leading cause of death and disability worldwide. Stem cell therapy is an emerging therapeutic modality with evidence of significant benefits in preclinical stroke models. A number of phase I and II clinical trials have now been completed, with several more currently under way. Translation to the bedside, however, remains a long way off, and there are many questions that remain unanswered. This review will summarize the current evidence and ongoing clinical trials worldwide, and explore the challenges to making this a realistic treatment option for the future.
中风是全球死亡和残疾的主要原因。干细胞疗法是一种新兴的治疗方式,在临床前中风模型中有显著益处的证据。目前已经完成了多项I期和II期临床试验,还有几项正在进行中。然而,将其应用于临床仍有很长的路要走,还有许多问题尚未得到解答。本综述将总结目前全球的证据和正在进行的临床试验,并探讨将其变为未来切实可行的治疗选择所面临的挑战。